Study on Von Willebrand Disease and Hemophilia in Cuenca, Ecuador

NCT ID: NCT01589848

Last Updated: 2013-07-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

81 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-03-31

Study Completion Date

2013-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

1. Hypothesis

a. There are patients with von Willebrand Disease in Cuenca.
2. Primary question

a. How many women referred with a history of bleeding may have von Willebrand disease?
3. Secondary

1. Associations between the bleeding score and initial laboratory studies
2. What are the differences on subgroups of enrolled patients with the bleeding score?
4. Ancillary

1. What is the clinical and socio-economic status of women with von Willebrand Disease in Cuenca?
2. What is the clinical and socio-economic status of patients with Hemophilia in Cuenca?

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The incidence of hemophilia A is 1 in 10,000 and the one of hemophilia B is 1 in 30,000 live born males. As the most frequent coagulopathy in the world, von Willebrand disease (vWD) can affect 1 in 1000 children of both genders. The prevalence of vWD is 1-2% and it may be as high as 5-15% among women with menorrhagia. So vWD can be present in 1 of every 100 to 500 individuals.

A world survey published that Ecuador, with a population of 14,790,608 people, has 238 patients with hemophilia, 45 people with von Willebrand disease (vWD) and 13 patients with other bleeding disorders including rare factor deficiencies and platelet disorders.

The Ecuadorian census of 2010 indicates that Cuenca district (canton) has 505,585 inhabitants. According to a local reference, Cuenca has no reports of vWD and it has registered 20-40 patients with hemophilia A and B. However Cuenca may host approximately 10,000 people with vWD because it affects both males and females. One plausible explanation for this lag is that the diagnostic suspicions of vWD had not been proven because of the lack of a special coagulation laboratory in Cuenca that would allow professionals to make a positive diagnosis.

This is the first clinical, demographic and socio-economic study of patients registered with hemophilia and of Cuenca women with possible vWD who are referred from dentists and physicians from public and private health centers. The instruments will be validated surveys and screening coagulation studies.

As far as we know Ecuador has not published studies on coagulopathies. Our aim is to initiate a process to eventually reach the goal to offer adequate diagnostic and therapeutic interventions to human victims of these diseases, within a program of service, teaching and research.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Von Willebrand Disease Hemophilia A Hemophilia B

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

von Willebrand women

Referred women who may have von Willebrand Disease

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects living at urban and rural parishes from Cuenca district.
* Subjects referred from professionals of public and private health services, who have filled the initial hemorrhage survey.
* Must be referred women who sign the informed consent form.
* Patients who answer the standardized bleeding score questionnaire (BS).
* Patients who answer the quality of life questionnaire (SF-12).
* Patients who answer the socio-economic survey.
* Patients who accept to provide a venous blood sample for the initial laboratory tests.

Exclusion Criteria

* Women with organic or hormonal bleeding etiologies.
* Patients taking medicines which may affect the coagulation cascade or the number or function of platelets.
Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Universidad del Azuay

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jaime M. Moreno A., M.D., M.S., F.A.C.P.

Jaime M. Moreno A, M.D., M.S., F.A.C.P.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jaime M. Moreno A., M.D., M.S.

Role: PRINCIPAL_INVESTIGATOR

Universidad del Azuay (UAzuay)

Jacinto Guillen G., Eng., M.S.

Role: STUDY_CHAIR

Universidad del Azuay (UAzuay)

Rodrigo Cueva M., Econ., M.S.

Role: STUDY_DIRECTOR

Universidad del Azuay (UAzuay)

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

UAzuay

Cuenca, Azuay, Ecuador

Site Status

Universidad del Azuay (UDA)

Cuenca, Azuay, Ecuador

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Ecuador

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

UAzuay

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.